Author | Â | N | Local recurrence, % | Overall survival, % (years) | Progression-free survival, % (years) |
---|---|---|---|---|---|
Nahi et al. [4] | Total | 191 | NR | 53% (8Â years) | 75% (2Â years) |
SBP | 124 | NR | 56% (8Â years) | 65% (2Â years) | |
EMP | 67 | NR | 51% (8Â years) | 94% (2Â years) | |
De Waal et al. [36] | Total | 100 | 0% | 68% (10Â years) | 50% (15Â years) |
SBP | 66 | 0% | 64%(10Â years) | 30% (15Â years) | |
EMP | 34 | 0% | 77% (10Â years) | 88% (15Â years) | |
Katodritou et al. [61] | Total | 97 | NR | 78% (10Â years) | 59% (10Â years) |
SBP | 65 | NR | 69% (10Â years) | 40% (10Â years) | |
EMP | 32 | NR | 86% (10Â years) | 50% (10Â years) | |
Reed et al. [48] | Total | 84 | 8% | 78% (5Â years) | 47% (5Â years) |
SBP | 59 | 3% | 76% (5Â years) | 56% (5Â years) | |
EMP | 25 | 20% | 85% (5Â years) | 30% (5Â years) | |
Kilciksiz et al. [45] | Total | 80 | 6% | 73% (10Â years) | NR |
SBP | 57 | 6% | 68% (10Â years) | NR | |
EMP | 23 | 5% | 89% (10Â years) | NR | |
Ozsahin et al. [5] | Total | 258 | 14% | 55% (10Â years) | 35% (10Â years) |
SBP | 206 | 14% | 52% (10Â years) | 28% (10Â years) | |
EMP | 52 | 14% | 72%(10Â years) | 74% (10Â years) | |
Tsang et al. [47] | Total | 46 | 17% | 65% (8Â years) | 50% (8Â years) |
SBP | 32 | 22% | NR | 36% (8Â years) | |
EMP | 14 | 7% | NR | 84% (8Â years) | |
Liebross et al. [24] | SBP | 57 | 4% | 50% (10Â years) | 47% (10Â years) |
Liebross et al. [3] | EMP | 22 | 7% | 50% (10Â years) | 68% (10Â years) |